| 产品名称 | BRD 73954 |
| 产品货号 | Axon 2471 CAS [1440209-96-0] MF C16H16N2O3MW 284.31 Purity: 99% Soluble in DMSO Description First dual HDAC 6/8 inhibitor (IC50 values 9000 nM, >33000 nM, 36 nM, and 120 nM for HDAC2, 4, 6, and 8. respectively) with excellent selectivity over the other class I and II HDACs tested (75- and 130-fold less potent for the next closest isoforms). Simultaneous inhibition of HDAC6 and HDAC8 has many potential therapeutic applications, providing a larger therapeutic window than inhibition of HDAC1–3. References Certificates Categories Extra info D.E. Olson et al. Discovery of the first histone deacetylase 6/8 dual inhibitors. J Med Chem. 2013 Jun 13;56(11):4816-20. G. Tang et al. Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors. J Med Chem. 2014 Oct 9;57(19):8026-34. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology Epigenetics DNA-damage Response EC 3.5.1.98 HDAC Dual HDAC 6/8 inhibitor with excellent selectivity over the other HDACs Chemical name N1-hydroxy-N3-phenethylisophthalamide Parent CAS No. [1440209-96-0] Order Size Unit Price Stock 5 mg €85.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
BRD 73954Axon 2471 CAS [1440209-96-0] MF C16H16N2O3
DescriptionFirst dual HDAC 6/8 inhibitor (IC50 values 9000 nM, >33000 nM, 36 nM, and 120 nM for HDAC2, 4, 6, and 8. respectively) with excellent selectivity over the other class I and II HDACs tested (75- and 130-fold less potent for the next closest isoforms). Simultaneous inhibition of HDAC6 and HDAC8 has many potential therapeutic applications, providing a larger therapeutic window than inhibition of HDAC1–3.
Dual HDAC 6/8 inhibitor with excellent selectivity over the other HDACs
Chemical nameN1-hydroxy-N3-phenethylisophthalamide Parent CAS No.[1440209-96-0] |
| 产品资料 |
